Aclaris Therapeutics to stop development of rheumatoid arthritis drug (updated)

Aclaris Therapeutics

13/11/2023 12:17

(Adds details in paragraphs 2 and 3, shares in paragraph 4)
       Nov 13 (Reuters) - Aclaris Therapeutics  ACRS.O  on
Monday said it would stop development of its rheumatoid
arthritis treatment after it failed in a mid-stage trial.
        There was no notable differentiation between the drug,
zunsemetinib, and placebo across any measures of efficacy at 12
weeks, the company said.
  
        The company will also be halting enrollment in an
ongoing mid-stage trial studying the drug in psoriatic
arthritis.
  
        Shares of the company were halted before the opening
bell.
  

 (Reporting by Sriparna Roy in Bengaluru; Editing by Maju
Samuel)
 ((Sriparna.Roy@thomsonreuters.com;))